LONDON–(BUSINESS WIRE)–EMMAC (“EMMAC” or the “Company”) , the leading European independent medical cannabis company, is pleased to announce a collaboration with the Center of Research in Medical Pharmacology at the Italian University of Insubria, to deliver a long-term research programme on screening of Cannabinoids through an ex vivo/in vitro human immune cells-based platform. The programme aims to investigate mechanisms of action and characterise cannabis-based medicinal products in disease models with a particular focus on the immune system and immunoinflammatory disease. The initial research will focus on multiple sclerosis, and the first stage is estimated to be completed by the last quarter of 2019.
The Center of Research in Medical Pharmacology at the University of Insubria has extensive experience in the characterisation of human adaptive and innate immunity through the use of ex vivo/in vitro experimental models based on human circulating immune cells.
Barbara Pacchetti, Chief Scientific Officer of EMMAC, commented:
“EMMAC is pleased to partner with the University of Insubria on a cannabinoid research programme focused across different therapeutic areas. Research provides valuable data and intellectual property in relation to the use of cannabinoids to treat spasticity, inflammation and chronic pain, with an initial focus on multiple sclerosis and continuing the collaboration with further research on various topics including atherosclerosis and cardiovascular events. EMMAC is committed to partnering with world-renowned institutions such as Imperial College London and University of Insubria, to further research to support the growth of the medical cannabis industry.”
Prof. Marco Cosentino, UNINSUBRIA, commented:
“The use of cannabinoids derived from the C. sativa plant are established in multiple sclerosis for the treatment of spasticity and chronic pain, however preclinical evidence suggests their potential as modulators of neuroinflammation. Characterisation of their immune effects on human immune responses relevant to multiple sclerosis physiopathology would pave the way to clinical assessment of their immunotherapeutic potential in multiple sclerosis. We strongly hope that the Partnership with EMMAC will speed up the translation of preclinical evidence in human cell-based experimental models towards clinical trials for the benefit of multiple sclerosis patients.”
EMMAC Life Sciences Ltd is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.
The Center for Research in Medical Pharmacology at the University of Insubria is an international leading center in the emerging field of neuroimmune pharmacology, a young but rapidly growing discipline encompassing interdisciplinary research in pharmacology, immunology and neuroscience, with the overarching goal to identify novel therapeutic approaches thanks to the investigations of the neuroimmune network. Basic and clinical research focus on the pathophysiology and therapeutics of major diseases such as multiple sclerosis, Parkinson’s disease, atherosclerosis and other immunoinflammatory-based disease. Clinical pharmacology, pharmacogenetics, pharmacoepidemiology and pharmacovigilance are included among the interests and approaches of the Center.
For scientific enquiries please contact firstname.lastname@example.org
All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences PLC. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences PLC assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.